{
  "id": 17829503,
  "title": "STAT+: Psilocybin’s lasting benefits prove elusive in mice",
  "url": "https://urgent.news/2026/11/02/stat-psilocybins-lasting-benefits-prove-elusive-in-mice",
  "topic": "science",
  "section": "Science",
  "published": "2026-11-02T16:47:33.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/11/02/biotech-news-psilocybin-lasting-benefits-prove-elusive-in-mice/"
  },
  "original_language": "en",
  "account": "UniQure announced the FDA accepted its AMT-130 gene therapy application for Huntington's disease treatment, with approval expected on May 1, 2027. The FDA is considering an advisory committee meeting to review the AMT-130 data. Meanwhile, a fertility treatment marketing itself as a biological clock reversal has created a global medical tourism industry, despite limited evidence to support its claims. An eight-month STAT investigation uncovered clinics and intermediaries promoting mitochondrial replacement, or \"three-parent IVF,\" to older women seeking genetically related children for tens of thousands of dollars. The piece continues in STAT+.",
  "summary": "Five Bay Area labs teamed up to compare lasting effects of psilocybin on anxiety and depression-like behavior in mice, with limited results:",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}